Management of Myocardial Infarction and the Role of Cardiothoracic Surgery

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Sep 28

PMID 39336971

Authors

Shannon Parness

Panagiotis Tasoudis

Chris B Agala

Aurelie E Merlo

Affiliations

Soon will be listed here.

Abstract

Myocardial infarction (MI) is a leading cause of mortality globally and is predominantly attributed to coronary artery disease (CAD). MI is categorized as ST-elevation MI (STEMI) or non-ST-elevation MI (NSTEMI), each with distinct etiologies and treatment pathways. The goal in treatment for both is restoring blood flow back to the myocardium. STEMI, characterized by complete occlusion of a coronary artery, is managed urgently with reperfusion therapy, typically percutaneous coronary intervention (PCI). In contrast, NSTEMI involves a partial occlusion of a coronary artery and is treated with medical management, PCI, or coronary artery bypass grafting (CABG) depending on risk scores and clinical judgment. The Heart Team approach can assist in deciding which reperfusion technique would provide the greatest benefit to the patient and is especially useful in complicated cases. Despite advances in treatment, complications such as cardiogenic shock (CS) and ischemic heart failure (HF) remain significant. While percutaneous coronary intervention (PCI) is considered the primary treatment for MI, it is important to recognize the significance of cardiac surgery in treatment, especially when there is complex disease or MI-related complications. This comprehensive review analyzes the role of cardiac surgery in MI management, recognizing when it is useful, or not.

References

Zalewski J, Nowak K, Furczynska P, Zalewska M . Complicating Acute Myocardial Infarction. Current Status and Unresolved Targets for Subsequent Research. J Clin Med. 2021; 10(24). PMC: 8705405. DOI: 10.3390/jcm10245904. View

Carson P, Wertheimer J, Miller A, OConnor C, Pina I, Selzman C . The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. JACC Heart Fail. 2014; 1(5):400-8. PMC: 3829618. DOI: 10.1016/j.jchf.2013.04.012. View

Sajgalik P, Grupper A, Edwards B, Kushwaha S, Stulak J, Joyce D . Current Status of Left Ventricular Assist Device Therapy. Mayo Clin Proc. 2016; 91(7):927-40. DOI: 10.1016/j.mayocp.2016.05.002. View

Turner K . Right Ventricular Failure After Left Ventricular Assist Device Placement-The Beginning of the End or Just Another Challenge?. J Cardiothorac Vasc Anesth. 2018; 33(4):1105-1121. DOI: 10.1053/j.jvca.2018.07.047. View

Del Buono M, Moroni F, Montone R, Azzalini L, Sanna T, Abbate A . Ischemic Cardiomyopathy and Heart Failure After Acute Myocardial Infarction. Curr Cardiol Rep. 2022; 24(10):1505-1515. PMC: 9556362. DOI: 10.1007/s11886-022-01766-6. View

Sui Y, Teng S, Qian J, Zhao Z, Zhang Q, Wu Y . Treatment outcomes and therapeutic evaluations of patients with left ventricular aneurysm. J Int Med Res. 2018; 47(1):244-251. PMC: 6384485. DOI: 10.1177/0300060518800127. View

Napp L, Kuhn C, Bauersachs J . ECMO in cardiac arrest and cardiogenic shock. Herz. 2017; 42(1):27-44. PMC: 5306351. DOI: 10.1007/s00059-016-4523-4. View

Benjamin E, Blaha M, Chiuve S, Cushman M, Das S, Deo R . Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017; 135(10):e146-e603. PMC: 5408160. DOI: 10.1161/CIR.0000000000000485. View

Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R . A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008; 52(19):1584-8. DOI: 10.1016/j.jacc.2008.05.065. View

10.

Pocar M, Moneta A, Grossi A, Donatelli F . Coronary artery bypass for heart failure in ischemic cardiomyopathy: 17-year follow-up. Ann Thorac Surg. 2007; 83(2):468-74. DOI: 10.1016/j.athoracsur.2006.09.029. View

11.

Rose E, Gelijns A, Moskowitz A, Heitjan D, Stevenson L, Dembitsky W . Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2002; 345(20):1435-43. DOI: 10.1056/NEJMoa012175. View

12.

Masi P, Gendreau S, Moyon Q, Leguyader M, Lebreton G, Ropers J . Bleeding complications, coagulation disorders, and their management in acute myocardial infarction-related cardiogenic shock rescued by veno-arterial ECMO: A retrospective cohort study. J Crit Care. 2024; 82:154771. DOI: 10.1016/j.jcrc.2024.154771. View

13.

Davis W, Montrief T, Koyfman A, Long B . Dysrhythmias and heart failure complicating acute myocardial infarction: An emergency medicine review. Am J Emerg Med. 2019; 37(8):1554-1561. DOI: 10.1016/j.ajem.2019.04.047. View

14.

Sleeper L, Ramanathan K, Picard M, Lejemtel T, White H, Dzavik V . Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol. 2005; 46(2):266-73. DOI: 10.1016/j.jacc.2005.01.061. View

15.

Anderson M, Goldstein J, Milano C, Morris L, Kormos R, Bhama J . Benefits of a novel percutaneous ventricular assist device for right heart failure: The prospective RECOVER RIGHT study of the Impella RP device. J Heart Lung Transplant. 2015; 34(12):1549-60. DOI: 10.1016/j.healun.2015.08.018. View

16.

Leacche M, Balaguer J, Byrne J . Role of cardiac surgery in the post-myocardial infarction patient with heart failure. Curr Heart Fail Rep. 2008; 5(4):204-10. DOI: 10.1007/s11897-008-0031-z. View

17.

Sachdeva P, Kaur K, Fatima S, Mahak F, Noman M, Siddenthi S . Advancements in Myocardial Infarction Management: Exploring Novel Approaches and Strategies. Cureus. 2023; 15(9):e45578. PMC: 10587445. DOI: 10.7759/cureus.45578. View

18.

Bounader K, Flecher E . End-stage heart failure: The future of heart transplant and artificial heart. Presse Med. 2023; 53(1):104191. DOI: 10.1016/j.lpm.2023.104191. View

19.

Schomig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F . Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005; 293(23):2865-72. DOI: 10.1001/jama.293.23.2865. View

20.

Gheorghiade M, Bonow R . Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998; 97(3):282-9. DOI: 10.1161/01.cir.97.3.282. View